Document:

Document

Exhibit 10.3

EXECUTION COPY
LETTER WAIVER
Dated as of June 8, 2021
To the banks, financial institutions
and other institutional lenders
(collectively, the “Lenders”)
parties to the Credit Agreement
referred to below and to Bank of America, N.A.,
as administrative agent (the “Administrative Agent”) for the Lenders
Ladies and Gentlemen:
We refer to the Credit Agreement dated as of March 8, 2019 (as amended, supplemented or otherwise modified through the date hereof, the “Credit Agreement”) among the undersigned (the “Borrower”) and you. Capitalized terms not otherwise defined in this Letter Waiver have the same meanings as specified in the Credit Agreement.
The Borrower entered into an Agreement and Plan of Merger, dated as of May 21, 2021, among the Borrower, Canadian National Railway Company (the “Acquiror”) and Brooklyn Merger Sub, Inc. (together with the exhibits and schedules thereto, the “Acquisition Agreement”), pursuant to which the Acquiror intends to acquire, directly or indirectly (the “Acquisition”), all of the issued and outstanding equity interests in the Borrower (together with its subsidiaries, the “Borrower Group”).  In connection with the Acquisition, the Borrower’s equity will be placed (the “Trust Closing”) into a voting trust (the “Voting Trust”) in accordance with the form of Voting Trust Agreement attached to the Acquisition Agreement (the “Voting Trust Agreement”).  Until such time as the Acquiror receives a final order of the Surface Transportation Board approving or exempting the acquisition of control of the Borrower Group by the Acquiror (the “Voting Trust Termination Date”), the Borrower will not be controlled by the Acquiror, and the Borrower’s equity will remain in the Voting Trust.  The Acquisition will involve the merger of a newly formed special purpose acquisition entity organized in the State of Delaware with and into the Borrower, with the Borrower surviving in accordance with clause (i) of Section 5.02(d)(iv) of the Credit Agreement.
We hereby request that you waive, solely for the period commencing on the date first above written through the Voting Trust Termination Date, the Event of Default which would arise pursuant to Section 6.01(k) of the Credit Agreement as a result of the Change of Control arising upon consummation of the Trust Closing.
We further hereby request that you waive, solely for the period commencing on the Voting Trust Termination Date and ending 60 days thereafter (the “Waiver Termination Date”), the Event of Default which would arise pursuant to Section 6.01(k) of the Credit Agreement as a result of the Change of Control arising upon the Acquiror obtaining control of the Borrower Group such that each member of the Borrower Group becomes a direct or indirect subsidiary of the Acquiror.
For the avoidance of doubt, the Lenders are not asked to waive the requirements of Section 5.02(d)(iv) of the Credit Agreement.

On the Waiver Termination Date, without any further action by the Administrative Agent and the Lenders, all of the terms and provisions set forth in the Credit Agreement with respect to Defaults or Events of Default thereunder that are waived hereby and not cured prior to such date shall have the same force and effect as if this Letter Waiver had not been entered into by the parties hereto, and the Administrative Agent and the Lenders shall have all of the rights and remedies afforded to them under the Credit Agreement with respect to any such Defaults or Events of Default as though no waiver had been granted by them hereunder.
To induce the Lenders to enter into this Letter Waiver, the Borrower represents and warrants that, as of the date hereof (a) the representations and warranties contained in each Loan Document (other than (x) the representation and warranty set forth in Section 4.01(f)(i) of the Credit Agreement and (y) the representation and warranty set forth in Section 4.01(g)(ii) of the Credit Agreement) are correct on and as of such date, as though made on and as of such date, other than any such representations or warranties that, by their terms, refer to a specific date, in which case as of such specific date; and (b) no Default has occurred and is continuing.
This Letter Waiver shall become effective as of the date first above written when, and only when, the Administrative Agent shall have received counterparts of this Letter Waiver executed by us and the Required Lenders, and the consent attached hereto executed by each Guarantor. This Letter Waiver is subject to the provisions of Section 9.01 of the Credit Agreement and shall constitute a Loan Document.
The Credit Agreement, except to the extent of the waivers specifically provided above, is and shall continue to be in full force and effect and is hereby in all respects ratified and confirmed. The execution, delivery and effectiveness of this Letter Waiver shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Administrative Agent under the Credit Agreement, nor constitute a waiver of any provision of the Credit Agreement.
If you agree to the terms and provisions of this Letter Waiver, please evidence such agreement by executing and returning a counterpart of this Letter Waiver to Susan L. Hobart, Shearman & Sterling LLP, (fax no: 646-848-7847; email: shobart@shearman.com) by no later than 3:00 p.m. (Eastern Time) on Monday, June 7, 2021.
This Letter Waiver may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Letter Waiver by telecopier shall be effective as delivery of a manually executed counterpart of this Letter Waiver in accordance with Section 9.19 of the Credit Agreement.
This Letter Waiver shall be governed by, and construed in accordance with, the laws of the State of New York.
        
2

Very truly yours,

KANSAS CITY SOUTHERN, as Borrower
By  /s/ Michael W. Upchurch    
Name:    Michael W. Upchurch
Title:    Executive Vice President & CFO

[Signature Page to Letter Waiver]

Agreed as of the date first above written:
BANK OF AMERICA, N.A., 
as a Lender
By  /s/ Adrian Plummer             
Name:    Adrian Plummer
Title:    Vice President
[Signature Page to Letter Waiver]

Agreed as of the date first above written:
Citibank, N.A., as Lender
By  /s/ Kevin Clark         
Name:    Kevin Clark
Title:    Vice President

[Signature Page to Letter Waiver]

Agreed as of the date first above written:
JPMORGAN CHASE BANK, N.A., as Lender

By  /s/ Jonathan Bennett         
Name:    Jonathan Bennett
Title:    Executive Director

[Signature Page to Letter Waiver]

Agreed as of the date first above written:
U.S. BANK NATIONAL ASSOCIATION, as Lender

By  /s/ Peter I Bystol          
Name:    Peter I. Bystol
Title:    Senior Vice President

[Signature Page to Letter Waiver]

Agreed as of the date first above written:
Wells Fargo Bank, N.A., as Lender

By  /s/ Tammy R. Henke    
Name:    Tammy R. Henke
Title:    Senior Vice President
[Signature Page to Letter Waiver]

Agreed as of the date first above written:
THE BANK OF NOVA SCOTIA, as Lender

By  /s/ David Vishny          
Name:    David Vishny
Title:    Managing Director
[Signature Page to Letter Waiver]

Agreed as of the date first above written:
Truist Bank, as Lender

By  /s/ Chris Hursey         
Name:    Chris Hursey
Title:    Director

[Signature Page to Letter Waiver]

Agreed as of the date first above written:
Goldman Sachs Bank USA, as Lender

By  /s/ Dan Martis         
Name:    Dan Martis
Title:    Authorized Signatory

[Signature Page to Letter Waiver]

MORGAN STANLEY BANK, N.A.,
as Lender
By  /s/ Jack Kuhns         
Name:    Jack Kuhns
Title:    Authorized Signatory

MORGAN STANLEY SENIOR FUNDING.,
as Lender
By  /s/ Jack Kuhns    
Name:    Jack Kuhns
Title:    Vice President

[Signature Page to Letter Waiver]

Acknowledged as of the date first above written:
BANK OF AMERICA, N.A.,
as Administrative Agent
By  /s/ Steven Gazzillo         
Name:    Steven Gazzillo
Title:    Vice President
[Signature Page to Letter Waiver]

CONSENT
Dated as of June 8, 2021

The undersigned, each a Guarantor under Article VIII of the Credit Agreement referred to in the foregoing Letter Waiver, hereby consents to such Letter Waiver and hereby confirms and agrees that notwithstanding the effectiveness of such Letter Waiver, the Guaranty is, and shall continue to be, in full force and effect and is hereby ratified and confirmed in all respects.
THE KANSAS CITY SOUTHERN RAILWAY COMPANY, as Guarantor
By  /s/ Michael W. Upchurch         
Name:    Michael W. Upchurch
Title:    Executive Vice President & CFO

GATEWAY EASTERN RAILWAY COMPANY, as Guarantor
By  /s/ Michael W. Upchurch         
Name:    Michael W. Upchurch
Title:    Vice President & CFO

SOUTHERN DEVELOPMENT COMPANY, as Guarantor
By  /s/ Michael W. Upchurch         
Name:    Michael W. Upchurch
Title:    Vice President, CFO & Treasurer

THE KANSAS CITY NORTHERN RAILWAY COMPANY, as Guarantor
By  /s/ Michael W. Upchurch         
Name:    Michael W. Upchurch
Title:    Vice President & CFO

[Signature Page to Letter Waiver]

TRANS-SERVE, INC., as Guarantor
By  /s/ Michael W. Upchurch         
Name:    Michael W. Upchurch
Title:    Vice President & CFO

PABTEX, INC., as Guarantor
By  /s/ Michael W. Upchurch         
Name:    Michael W. Upchurch
Title:     Vice President, CFO & Treasurer

KCS HOLDINGS, I, INC., as Guarantor
By  /s/ Michael W. Upchurch         
Name:    Michael W. Upchurch
Title:    Vice President & CFO

KCS VENTURES I, INC., as Guarantor
By  /s/ Michael W. Upchurch         
Name:    Michael W. Upchurch
Title:    Vice President & CFO

SOUTHERN INDUSTRIAL SERVICES, INC., as Guarantor
By  /s/ Michael W. Upchurch         
Name:    Michael W. Upchurch
Title:    Vice President, CFO & Treasurer

VEALS, INC., as Guarantor
By  /s/ Michael W. Upchurch         
Name:    Michael W. Upchurch
Title:    Vice President, CFO & Treasurer

[Signature Page to Letter Waiver]EX-4.1

 Exhibit 4.1 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of April 16, 2021, by
and among Adagio Therapeutics, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any
Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof. 

RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) possess registration rights, information rights, rights
of first offer, and other rights pursuant to an Amended and Restated Investors’ Rights Agreement, dated as of October 30, 2020, by and among the Company and such Existing Investors (the “Prior Agreement”); 

WHEREAS, the Existing Investors, who have sufficient shares to amend and restate the Prior Agreement in accordance with its terms,
desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement; 

WHEREAS, the Company and certain of the Investors are parties to that certain Series C Preferred Stock Purchase Agreement of even date
herewith (as the same may be amended and/or restated from time to time, the “Purchase Agreement”); and 
 WHEREAS,
in order to induce the Company to enter into the Purchase Agreement and to induce certain of the Investors to invest funds in the Company pursuant to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement shall govern
the rights of the Investors to cause the Company to register shares of Common Stock issuable to the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company and shall govern certain
other matters as set forth in this Agreement; 
 NOW, THEREFORE, the Company and the Existing Investors hereby agree to amend and
restate the Prior Agreement in its entirety as set forth herein, and all of the parties hereto further agree as follows: 
 1.
Definitions. For purposes of this Agreement: 
 1.1 “Affiliate” means, with respect to any specified Person, any
other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer, director or trustee of such Person or any venture capital
fund, registered investment company or fund or any other entity now or hereafter existing that is controlled by one or more general partners, managing members or investment adviser of, or shares the same management company or investment adviser
with, such Person. For the avoidance of doubt, each of Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund, Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund, Fidelity Growth Company Commingled Pool, Fidelity Mt.
Vernon Street Trust: Fidelity Growth Company K6 Fund and Fidelity Select Portfolios: Biotechnology Portfolio (each, a “Fidelity Investor,” and together, the “Fidelity Investors”) and any other fund or account
that is an entity advised or sub-advised by Fidelity Management & Research Company LLC shall be deemed Affiliates of each other. 

 1.2 “Board” means the board of directors of the Company. 

1.3 “Certificate of Incorporation” means the Company’s Amended and Restated Certificate of Incorporation, as amended
and/or restated from time to time. 
 1.4 “Common Stock” means shares of the Company’s common stock, par value $0.0001
per share. 
 1.5 “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may
become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged
untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged
omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of
the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.6 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each
case, directly or indirectly), Common Stock, including options and warrants. 
 1.7 “Exchange Act” means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.8 “Excluded Registration”
means (i) a registration relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a registration relating to an SEC Rule 145
transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; (iv) a registration in
which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered; or (v) a registration relating to the IPO. 

1.9 “Form S-1” means such form under the Securities Act as in effect on the date
hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.10 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of
substantial information by reference to other documents filed by the Company with the SEC. 

  
 2 

 1.11 “GAAP” means generally accepted accounting principles in the United
States as in effect from time to time. 
 1.12 “Holder” means any holder of Registrable Securities who is a party to this
Agreement. 
 1.13 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse,
life partner or similar statutorily-recognized domestic partner, sibling, mother-in-law,
father-in-law, son-in-law, daughter-in-law, brother-in-law, or
sister-in-law, including adoptive relationships, of a natural person referred to herein. 

1.14 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 1.15 “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act.

 1.16 “Key Employee” means any executive-level employee (including division director and vice president-level positions)
as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase Agreement). 

1.17 “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates, continues to
hold (i) at least 10% of the shares of Series A Preferred Stock acquired from the Company pursuant to that certain Series A Preferred Stock Purchase Agreement dated as of July 9, 2020, as the same may be amended and/or restated from time
to time, or, in the case of Adimab, LLC, at least 500,000 shares of Series A Preferred Stock (in each case, as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof);
(ii) at least 10% of the shares of Series B Preferred Stock acquired by such Investor from the Company pursuant to the Series B Purchase Agreement dated as of October 30, 2020, as the same may be amended and/or restated from time to time or
(iii) at least 128,064 shares of Series C Preferred Stock (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

1.18 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as
rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.19 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 1.20 “Preferred Stock” means, collectively, shares of the Series A Preferred Stock, the Series B Preferred Stock and the
Series C Preferred Stock. 

  
 3 

 1.21 “Registrable Securities” means (i) the Common Stock issuable or
issued upon conversion of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors prior to the
IPO; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the
shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to
Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 

1.22 “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of
outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.23 “Restricted Securities” means the securities of the Company required to be notated with the legend set forth in
Subsection 2.12(b) hereof. 
 1.24 “SEC” means the Securities and Exchange Commission. 

1.25 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.26 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.27 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.28 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6. 

1.29 “Series A Director” means each director of the Company that the holders of record of the Series A Preferred Stock are
entitled to elect, exclusively and as a separate class, pursuant to the Certificate of Incorporation. 
 1.30 “Series
A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.0001 per share. 
 1.31
“Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.0001 per share. 

1.32 “Series C Preferred Stock” means shares of the Company’s Series C Preferred Stock, par value $0.0001 per share.

  
 4 

 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) five (5) years after
the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding
that the Company file a Form S-1 registration statement for which the anticipated aggregate offering price would exceed $10 million, then the Company shall (i) within ten (10) days after the
date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within sixty (60) days after the date such request
is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional
Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject
to the limitations of Subsection 2.1(c) and Subsection 2.3. 
 (b) Form S-3
Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least thirty percent (30%) of the Registrable Securities then
outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price of at least
$1 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within
forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be
included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsection
2.1(c) and Subsection 2.3. 
 (c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a
registration pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board it would be materially detrimental to the Company and its stockholders for
such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant
acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or
(iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or
effectiveness thereof shall be tolled correspondingly, for a period of not more than ninety (90) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than
once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such ninety (90) day period other than an Excluded
Registration. 

  
 5 

 (d) The Company shall not be obligated to effect, or to take any action to effect, any
registration pursuant to Subsection 2.1(a)(i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the
effective date of, a Company-initiated registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has
effected two registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3
pursuant to a request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i) during the period that is thirty
(30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided, that the Company is actively
employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month
period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by
the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case
such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d); provided, that if such withdrawal is during a period the Company has deferred taking action pursuant to Subsection
2.1(c), then the Initiating Holders may withdraw their request for registration and such registration will not be counted as “effected” for purposes of this Subsection 2.1(d). 

2.2 Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for
stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give
each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3, cause to be registered all
of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Subsection 2.2 before the effective
date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with
Subsection 2.6. 
 2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and
shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such 

  
 6 

 
underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such
underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this
Subsection 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of
Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating
Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number
of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above
provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 

(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Subsection
2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only
in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in
such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the
offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than
all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable
to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the
Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless
all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total
number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are
included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners,
retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be
deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling
Holder,” as defined in this sentence. 

  
 7 

 (c) For purposes of Subsection 2.1, a registration shall not be counted as
“effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested
to be included in such registration statement are actually included. 
 2.4 Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period
of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of
Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be
extended for up to sixty (60) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 

  
 8 

 (f) use its commercially reasonable efforts to cause all such Registrable Securities
covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available
for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling
Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

 2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 
 2.6
Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification
fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements of one counsel for the selling Holders selected by the Holders of a majority of the Registrable Securities to be
registered (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to
Subsection 2.1 if the registration request is subsequently withdrawn at the request of 

  
 9 

 
the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that
were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Subsection 2.1(a) or Subsection 2.1(b), as the case may be;
provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request
and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsection
2.1(a) or Subsection 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable
Securities registered on their behalf. 
 2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction
restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling
Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel, accountants and investment advisers for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each
Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person
any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement
contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall
the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling
Person, or other aforementioned Person expressly for use in connection with such registration. 
 (b) To the extent permitted by law, each
selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of
the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder
expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal 

  
 10 

 
or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided,
however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent
shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsection 2.8(b) and Subsection 2.8(d) exceed the
proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action (including
any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8, give the indemnifying
party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been
given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one
counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due
to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such
action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure
to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i) any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such
case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the
aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party
in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of
the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access 

  
 11 

 
to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case, (x) no Holder will be required to contribute any
amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this
Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in
the case of willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on
indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the
termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the
benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form
S-3, the Company shall: 
 (a) make and keep available adequate current public information, as those
terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 
 (c)
furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any
time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or
that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company
and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without
registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

  
 12 

 2.10 Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that
would (i) provide to such holder or prospective holder the right to include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the
opportunity to include in the registration and offering all shares of Registrable Securities that they wish to so include or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such
holder or prospective holder; provided that this limitation shall not apply to Registrable Securities acquired by any additional Investor that becomes a party to this Agreement in accordance with Subsection 6.9. 

2.11 “Market Stand-off” Agreement. Each Holder hereby agrees that it
will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO and ending on the date specified by the Company and the managing underwriter (such period
not to exceed one hundred eighty (180) days), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise
transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration
statement for the IPO or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause
(i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall apply only to the IPO, shall not apply to the sale of any shares to an
underwriter pursuant to an underwriting agreement for such IPO, and shall be applicable to the Holders only if all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain a similar
agreement from all stockholders individually owning more than one percent (1%) of the outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding shares of Preferred Stock). If any of the obligations described in
this Subsection 2.11 are waived or terminated with respect to any of the securities of any officer, director or greater than one-percent stockholder (in any such case, the “Released
Securities”), the restrictions in this Subsection 2.11 shall be waived or terminated with respect to the Fidelity Investors, as applicable, to the same extent and with respect to the same percentage of securities of each Fidelity
Investor as the percentage of Released Securities represent with respect to the securities held by the applicable officer, director or greater than one-percent stockholder. The underwriters in connection with
such registration are intended third party beneficiaries of this Subsection 2.11 and shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such
agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give further effect thereto. Any discretionary waiver or termination of
the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Company stockholders that are subject to such agreements, based on the number of shares subject to such agreements. 

  
 13 

 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred in violation of this Agreement,
and the Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure
compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities
subject to the provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144,
in each case, to be bound by the terms of this Agreement. 
 (b) Each certificate, instrument or book entry representing (i) the
Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or
similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND
THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in
its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of
this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction or following the IPO,
the transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer provided that no such notice shall be required in connection if the intended
sale, pledge or transfer complies with SEC Rule 144. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at
such Holder’s expense by either (i) a written opinion of legal counsel who shall, 

  
 14 

 
and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the
Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that
action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration
under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will
not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144 or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no
consideration (or for consideration with respect to Redmile Biopharma Investments III, L.P. and RAF, L.P.); provided that other than in connection with a transaction in compliance with SEC Rule 144 following the IPO, each transferee agrees in
writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC
Rule 144 or pursuant to an effective registration statement, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such certificate, instrument or book entry shall not be notated with such restrictive legend if, in
the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 

2.13 Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any
registration pursuant to Subsection 2.1 or Subsection 2.2 shall terminate upon the earliest to occur of: 
 (a) immediately
before the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation; 
 (b) such time after
consummation of the IPO as SEC Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration; and 

(c) the fifth (5th) anniversary of the IPO. 

3. Information. 
 3.1
Delivery of Financial Statements. So long as at least 2,250,000 shares of Registrable Securities (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to
the Registrable Securities) are outstanding, the Company shall deliver to each Major Investor, provided that the Board has not reasonably determined that such Major Investor is a competitor of the Company (provided that the Fidelity Investors
shall not be deemed or determined to be competitors of the Company): 

  
 15 

 (a) as soon as practicable, but in any event within 90 days after the end of each fiscal
year of the Company beginning with the fiscal year ending December 31, 2020 (or such other time as approved by the Board), (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and
a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year, with an explanation of any material differences between such amounts and a schedule as to the sources and
applications of funds for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and certified by independent public accountants of recognized standing selected by the
Company; 
 (b) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three
(3) quarters of each fiscal year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that
such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); and 

(c) as soon as practicable, but in any event within thirty (30) days of the end of each month, an unaudited income statement for such
month, and an unaudited balance sheet as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and
(ii) not contain all notes thereto that may be required in accordance with GAAP). 
 If, for any period, the Company has any subsidiary
whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all
such consolidated subsidiaries. 
 Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease
providing the information set forth in this Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of submission of a registration statement if it reasonably
concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company
is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 
 3.2
Inspection. So long as at least 2,250,000 shares of Registrable Securities (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Registrable
Securities) are outstanding, the Company shall permit each Major Investor (provided that the Board has not reasonably determined that such Major Investor is a competitor of the Company; provided further that the Fidelity
Investors shall not be deemed or determined to be competitors of the Company), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s
affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this
Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the
Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

  
 16 

 3.3 Termination of Information Rights. The covenants set forth in
Subsection 3.1 and Subsection 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic
reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 

3.4 Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any
purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless
such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.4 by such Investor), (b) is or has been independently developed or conceived by such
Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company;
provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its
investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Subsection 3.4; (iii) to any existing or
prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person
to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, regulation, rule, court order or subpoena, provided that such Investor promptly notifies the Company of such disclosure and takes
reasonable steps to minimize the extent of any such required disclosure. 
 4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable
securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it
among itself and its Affiliates in such proportions as it deems appropriate; provided that each such Affiliate agrees to enter into this Agreement and each of the Second Amended and Restated Voting Agreement of even date herewith among
the Company, the Investors and the other parties named therein (as it may be amended and/or restated from time to time, the “Voting Agreement”) and the Second Amended and Restated Right of First Refusal and Co-Sale Agreement of even date herewith among the Company, the Investors and the other parties named therein, as an “Investor” under each such agreement. 

  
 17 

 (a) The Company shall give notice (the “Offer Notice”) to each Major
Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including all shares of Common Stock then
issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock of the Company then outstanding (assuming
full conversion and/or exercise, as applicable, of all Preferred Stock and any other Derivative Securities then outstanding). At the expiration of such twenty (20) day period, the Company shall promptly notify each Major Investor that elects to
purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such
notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to
subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any
other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative
Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of ninety (90) days of the date that the Offer
Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c). 
 (c) If all New Securities referred
to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in
Subsection 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the
Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be
deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance with this Subsection 4.1. 

(d) The right of first offer in this Subsection 4.1 shall not be applicable to (i) Exempted Securities (as defined in the
Certificate of Incorporation); (ii) shares of Common Stock issued in the IPO; or (iii) the issuance of shares of Series C Preferred Stock to Additional Purchasers pursuant to Subsection 1.3 of the Purchase Agreement. 

(e) Notwithstanding any provision hereof to the contrary, in lieu of complying with the provisions of this Subsection 4.1, the Company
may elect to give notice to the Major Investors within thirty (30) days after the issuance of New Securities. Such notice shall describe the type, price, and terms of the New Securities. Each Major Investor shall have twenty (20) days from
the date notice is given to elect to purchase up to the number of New Securities that would, if purchased by such Major Investor, maintain such Major Investor’s percentage-ownership position, calculated as set forth in Subsection 4.1(b)
before giving effect to the issuance of such New Securities. 

  
 18 

 4.2 Termination. The covenants set forth in Subsection 4.1 shall terminate and
be of no further force or effect (a) immediately before the consummation of the IPO, (b) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act or (c) upon the
closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 
 5.
Additional Covenants. 
 5.1 Insurance. The Company shall obtain, within ninety (90) days of the date hereof, from
financially sound and reputable insurers, Directors and Officers liability insurance in an amount and on terms and conditions satisfactory to the Board, and will use commercially reasonable efforts to cause such insurance policy to be maintained
until such time as the Board determines that such insurance should be discontinued. The policy shall not be cancelable by the Company without prior approval by the Board. 

5.2 Employee Agreements. The Company will cause (i) each Person now or hereafter employed by it or by any subsidiary (or engaged
by the Company or any subsidiary as a consultant or independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement and (ii) each Key Employee to
enter into a one (1) year (or lesser duration as required by applicable law) noncompetition and nonsolicitation agreement, each in a form acceptable to the Board, including a majority of the Series A Directors. In addition, the Company shall
not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the prior approval of the Board, including a
majority of the Series A Directors. 
 5.3 Employee Stock. Unless otherwise approved by the Board, including a majority of the Series
A Directors, or the Compensation Committee of the Board, including the Mithril Designee (as defined in the Voting Agreement) or the Polaris Designee (as defined in the Voting Agreement), all future employees and consultants of the Company who
purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares
over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following
thirty-six (36) months, subject to acceleration upon a change of control, and (ii) a market stand-off provision substantially similar to that in Subsection
2.11. Without the prior approval by the Board, including a majority of the Series A Directors, or the Compensation Committee of the Board, including the Mithril Designee (as defined in the Voting Agreement) or the Polaris Designee (as defined in
the Voting Agreement), the Company shall not amend, modify, terminate, waive or otherwise alter, in whole or in part, any stock purchase, stock restriction or option agreement with any existing employee or service provider if such amendment would
cause it to be inconsistent with this Subsection 5.3. In addition, unless otherwise approved by the Board, including a majority of the Series A Directors, 

  
 19 

 
or the Compensation Committee of the Board, including the Mithril Designee (as defined in the Voting Agreement) or the Polaris Designee (as defined in the Voting Agreement), the Company shall
retain (and not waive) a “right of first refusal” on employee transfers until the IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 

5.4 Matters Requiring Series A Director Approval. So long as the holders of Series A Preferred Stock are entitled, as a separate class,
to elect a Series A Director, the Company hereby covenants and agrees with the Investors that it shall not, without approval of the Board, which approval must include the affirmative vote of a majority of the Series A Directors: 

(a) incur any indebtedness for borrowed money in excess of $500,000 in a single or series of related transactions; or 

(b) increase the shares of Common Stock reserved for issuance under the Company’s 2020 Equity Incentive Plan or adopt any other equity
incentive plan. 
 5.5 Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the
Board shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors for all reasonable out-of-pocket
travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board. The Company shall cause to be established, as soon as practicable after request of the Board and will maintain, an audit
and compensation committee, each of which shall consist solely of non-management directors. Each non-employee director shall be entitled in such person’s discretion
to be a member of any committee of the Board. 
 5.6 Successor Indemnification. If the Company or any of its successors or assignees
consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the
Company assume the obligations of the Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, the Certificate of
Incorporation, or elsewhere, as the case may be. 
 5.7 Indemnification Matters. The Company hereby acknowledges that directors
nominated to serve on the Board by the Investors (each an “Investor Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their
Affiliates (collectively, the “Investor Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Investor Director are primary and any obligation of the
Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Investor Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such
Investor Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Investor Director to the extent legally permitted and as required by the Certificate of
Incorporation or Bylaws of the Company (or any agreement between the Company and such Investor Director), without regard to any rights such Investor Director may have against the 

  
 20 

 
Investor Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution,
subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Investor Indemnitors on behalf of any such Investor Director with respect to any claim for which such Investor
Director has sought indemnification from the Company shall affect the foregoing and the Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of
such Investor Director against the Company. The Investor Directors and the Investor Indemnitors are intended third-party beneficiaries of this Subsection 5.7 and shall have the right, power and
authority to enforce the provisions of this Subsection 5.7 as though they were a party to this Agreement. 
 5.8 Right to Conduct
Activities. The Company hereby agrees and acknowledges that certain of the Investors (including without limitation, each Fidelity Investor, RA Capital, BCIP Life Sciences Associates, LP, Bain Capital Life Sciences Fund II, L.P., Redmile
Biopharma Investments III, L.P., RAF, L.P., Polaris Venture Partners Entrepreneurs’ Fund V, L.P., Polaris Venture Partners Founders’ Fund V, L.P., Polaris Venture Partners Special Founders’ Fund V, L.P., Polaris Venture Partners V,
L.P., Polaris Partners IX, L.P., Polaris Healthcare Technology Opportunities Fund, L.P., Mithril II LP and their Affiliates) are a professional investment organization and that such Investors (together with their Affiliates) review the business
plans and related proprietary information of many enterprises, some of which may compete directly or indirectly with the Company’s business (as currently conducted or as currently propose to be conducted). The Company hereby agrees that, to the
extent permitted under applicable law, such Investors (and their Affiliates) shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by such Investors (or their Affiliates) in any entity competitive
with the Company, or (ii) actions taken by any partner, officer, employee or other representative of such Investors (or their Affiliates) to assist any such competitive company, whether or not such action was taken as a member of the board of
directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated
with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company.

 5.9 Disclosure of Side Letters. If subsequent to the date hereof, the Company enters into any side letter or similar agreement
with any other Investor, such letter or similar agreement shall be disclosed to RA Capital. 
 5.10 Termination of Covenants. The
covenants set forth in this Section 5, except for Subsection 5.6 and Subsection 5.7, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when
the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) immediately prior to a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation,
whichever event occurs first. 

  
 21 

 5.11 Anti-Harassment Policy. The Company shall, within ninety (90) days
following the Closing (as defined in the Purchase Agreement), adopt and thereafter maintain in effect (i) a Code of Conduct governing appropriate workplace behavior and (ii) an Anti-Harassment and Discrimination Policy prohibiting
discrimination and harassment at the Company. Such policy shall be reviewed and approved by the Board of Directors. 
 5.12 FCPA. The
Company covenants that it shall not (and shall not permit any of its subsidiaries or Affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or
make any payment to, or otherwise contribute any item of value to, directly or indirectly, to any third party, including any Non-U.S. Official (as such term is defined in the U.S. Foreign Corrupt Practices Act
of 1977, as amended (the “FCPA”)), in each case, in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further covenants that it shall (and shall cause each of its
subsidiaries and Affiliates to) cease all of its or their respective activities, as well as remediate any actions taken by the Company, its subsidiaries or Affiliates, or any of their respective directors, officers, managers, employees, independent
contractors, representatives or agents in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further covenants that it shall (and shall cause each of its subsidiaries and Affiliates
to) maintain systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption
law. Upon request, the Company agrees to provide responsive information and/or certifications concerning its compliance with applicable anti-corruption laws. The Company shall promptly notify each Investor if the Company becomes aware of any
Enforcement Action (as defined in the Purchase Agreement). The Company shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to comply with the FCPA. The Company shall
use its best efforts to cause any direct or indirect subsidiary, whether now in existence or formed in the future, to comply in all material respects with all applicable laws. 

5.13 Cybersecurity. The Company shall, within one hundred eighty (180) days following the Closing (as defined in the Purchase
Agreement), use commercially reasonable efforts to (a) identify and restrict access (including through physical and/or technical controls) to the Company’s confidential business information and trade secrets and any information about
identified or identifiable natural persons maintained by or on behalf of the Company (collectively, “Protected Data”) to those individuals who have a need to access it and (b) implement reasonable physical, technical and
administrative safeguards designed to protect the confidentiality, integrity and availability of its technology and systems (including servers, laptops, desktops, cloud, containers, virtual environments and data centers) and all Protected Data. The
Company shall evaluate on a periodic basis at least annually whether such safeguards should be updated to maintain a level of security appropriate to the risk posed to Company systems and Protected Data. The Company shall educate its employees about
the proper use and storage of Protected Data, including periodic training as determined reasonably necessary by the Company or the Board of Directors. 

  
 22 

 6. Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a
transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or
(iii) after such transfer, holds at least 175,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that
(x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; (y) such
transferee is not a competitor of the Company (provided that the Fidelity Investors shall not be deemed or determined to be competitors of the Company); and (z) such transferee agrees in a written instrument delivered to the Company to be bound
by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee
(1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated
together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall, as a condition to the applicable transfer, establish a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to
the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors
and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2 Governing Law. This Agreement and any controversy arising out of or relating to this Agreement shall be governed by and construed
in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to conflict of law principles that would result in the application of any law other than the law of the Commonwealth of Massachusetts. 

6.3 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other
transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. 

(a) All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given
upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail during the recipient’s normal business hours, and if not sent during normal business hours, then on
the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a
nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the

  
 23 

 
respective parties at their addresses as set forth on Schedule A hereto or as on the books of the Company, or to the principal office of the Company and to the attention
of the Chief Executive Officer, in the case of the Company, or to such electronic mail address or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, it shall be
sent to 303 Wyman Street, Unit 303, Waltham, Massachusetts 02451, Attention: Tillman U. Gerngross; Email: tillman.gerngross@adimab.com and a copy (which shall not constitute notice) shall also be sent to Cooley LLP, 500 Boylston Street, 14th Floor,
Boston, MA 02116-3736, Attention: Ryan S Sansom, Email: rsansom@cooley.com and if notice is given to the Purchasers, a copy (which shall not constitute notice) shall also be given to Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street,
Boston, MA 02109, Attention: Jason L. Kropp, Email: jason.kropp@wilmerhale.com. 
 (b) Consent to Electronic Notice. Each Investor
consents to the delivery of any stockholder notice pursuant to the General Corporation Law of the State of Delaware (the “DGCL”), as amended or superseded from time to time, by electronic transmission pursuant to Section 232 of
the DGCL (or any successor thereto) at the electronic mail address set forth below such Investor’s name on Schedule A hereto, as updated from time to time by notice to the Company, or as on the books of the Company. Each Investor agrees
to promptly notify the Company of any change in such stockholder’s electronic mail address, and that failure to do so shall not affect the foregoing. 

6.6 Amendments and Waivers. Any term of this Agreement may be amended, modified or terminated and the observance of any term of this
Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding;
provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of
Subsection 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the
foregoing, (a) this Agreement may not be amended, modified or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, modification,
termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the
same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction), (b) Subsection 3.1 and Subsection 3.2,
Section 4 and any other section of this Agreement applicable to the Major Investors (including this clause (b) of this Subsection 6.6) may not be amended, modified, terminated or waived without the written
consent of the holders of a majority of the Registrable Securities then outstanding and held by the Major Investors, (c) any amendment, waiver or termination of any provision of this Agreement that references the Fidelity Investors and
adversely affects the Fidelity Investors will not be effective as it relates to the Fidelity Investors without the prior written consent of the Fidelity Investors holding a majority of the Registrable Securities held by the Fidelity Investors (the
“Requisite Fidelity Consent”), (d) if the provisions of Section 4 are waived with respect to a particular offering of New Securities by Major Investors constituting the required parties to effect such a
waiver (each, a “Waiving Major Investor”) and without the Requisite Fidelity Consent, and any 

  
 24 

 
such Waiving Major Investor then purchases New Securities in such offering, then the Company shall, after such offering, provide each Fidelity Investor with the right to elect to purchase up to
the number of New Securities that are allocated for purchase by the Major Investors equal to each such Fidelity Investor’s percentage-ownership position, calculated as set forth in Subsection 4.1(b) before giving effect to the issuance
of such New Securities multiplied by the total number of New Securities that are allocated for purchase by the Major Investors, (e) if the provisions of Section 4 are waived with respect to a particular offering of New
Securities by the Waiving Major Investors and without the prior written consent of BCIP Life Sciences Associates, LP and Bain Capital Life Sciences Fund II, L.P., and any such Waiving Major Investor then purchases New Securities in such offering,
then the Company shall, after such offering, provide BCIP Life Sciences Associates, LP and Bain Capital Life Sciences Fund II, L.P. with the right to elect to purchase up to the number of New Securities that are allocated for purchase by the Major
Investors equal to each of BCIP Life Sciences Associates, LP and Bain Capital Life Sciences Fund II, L.P’s percentage-ownership position, calculated as set forth in Subsection 4.1(b) before giving effect to the issuance of such New
Securities multiplied by the total number of New Securities that are allocated for purchase by the Major Investors and (f) if the provisions of Section 4 are waived with respect to a particular offering of New
Securities by the Waiving Major Investors and without the prior written consent of Redmile Biopharma Investments III, L.P. and RAF, L.P., and any such Waiving Major Investor then purchases New Securities in such offering, then the Company shall,
after such offering, provide Redmile Biopharma Investments III, L.P. and RAF, L.P. with the right to elect to purchase up to the number of New Securities that are allocated for purchase by the Major Investors equal to each of Redmile Biopharma
Investments III, L.P. and RAF, L.P’s percentage-ownership position, calculated as set forth in Subsection 4.1(b) before giving effect to the issuance of such New Securities multiplied by the total number of New Securities that are
allocated for purchase by the Major Investors. Notwithstanding the foregoing, Schedule A hereto may be amended by the Company from time to time to add transferees of any Registrable Securities in compliance with the terms of this Agreement
without the consent of the other parties; and Schedule A hereto may also be amended by the Company after the date of this Agreement without the consent of the other parties to add information regarding any additional Investor who becomes a
party to this Agreement in accordance with Subsection 6.9. Any amendment, modification, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on all parties hereto, regardless of
whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term,
condition, or provision. 
 6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason
held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and
construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 
 6.8 Aggregation of Stock. All
shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves
in any manner they deem appropriate. 

  
 25 

 6.9 Additional Investors. Notwithstanding anything to the contrary contained herein,
if the Company issues additional shares of Preferred Stock after the date hereof, whether pursuant to the Purchase Agreement or otherwise, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and
delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by
such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 

6.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and
agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement, the
Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. 

6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of
the Commonwealth of Massachusetts and to the jurisdiction of the United States District Court for the District of Massachusetts for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not
to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of the Commonwealth of Massachusetts or the United States District Court for the District of Massachusetts, and (c) hereby
waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune
from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such
court. 
 WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING
OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE
FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS
BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH
PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 

  
 26 

 6.12 Delays or Omissions. No delay or omission to exercise any right, power, or
remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a
waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter
occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.13 Massachusetts Business Trust. A copy of the Declaration of Trust of each Fidelity Investor or any Affiliate thereof is on file
with the Secretary of State of the Commonwealth of Massachusetts and notice is hereby given that this Agreement has been executed on behalf of the trustees of such Fidelity Investor or any Affiliate thereof as trustees and not individually and that
the obligations of this Agreement are not binding on any of the trustees, officers or stockholders of such Fidelity Investor or any Affiliate thereof individually but are binding only upon such Fidelity Investor or any Affiliate thereof and its
assets and property. 
 [Remainder of Page Intentionally Left Blank] 

  
 27 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	ADAGIO THERAPEUTICS, INC.
		
	By:	 	

	Name:	 	Tillman U. Gerngross, Ph.D.
	Title:	 	President

 Signature Page to 2nd Amended and Restated
Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	RA CAPITAL HEALTHCARE FUND, L.P.
	
	By: RA Capital Healthcare Fund GP, LLC, its General Partner

 
			
		
	By:	 	

 
			
	Name: Peter Kolchinsky
	Title: Manager
	
	RA CAPITAL NEXUS FUND II, L.P.
	
	By: RA Capital Nexus Fund II GP, LLC, its General Partner

 
			
		
	By:	 	

 
			
	Name: Peter Kolchinsky
	Title: Manager

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	ADIMAB, LLC

 
			
		
	By:	 	

 
			
	Name: Tillman U. Gerngross, Ph.D.
	Title: President

 Signature Page to 2nd Amended and Restated
Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	FEDERATED HERMES KAUFMANN SMALL
	CAP FUND
	
	By: Federated Global Investment Management
	Corp., as attorney-in-fact for Federated Hermes
	Kaufmann Small Cap Fund,
a portfolio of Federated Hermes Equity Funds

 
			
		
	By:	 	

 
			
	Name: Stephen Van Meter
	Title: Vice President and Chief Compliance Officer
	
	FEDERATED HERMES KAUFMANN FUND
	
	By: Federated Global Investment Management
	Corp., as attorney-in-fact for Federated Hermes
	Kaufmann Fund,
a portfolio of Federated Hermes Equity Funds

 
			
		
	By:	 	

 
			
	Name: Stephen Van Meter
	Title: Vice President and Chief Compliance Officer
	
	FEDERATED HERMES KAUFMANN FUND II
	
	By: Federated Global Investment Management
	Corp., as attorney-in-fact for Federated Hermes
	Kaufmann Fund II,
a portfolio of Federated Hermes Equity Funds

 
			
		
	By:	 	

 
			
	Name: Stephen Van Meter
	Title: Vice President and Chief Compliance Officer

 Signature Page to 2nd Amended and Restated
Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	OMEGA FUND VI, L.P.
	
	By: Omega Fund VI GP, L.P., its General Partner
	By: Omega Fund VI GP Manager, Ltd., its General
	Partner

 
			
		
	By:	 	

 
			
	Name:  Otello Stampacchia
	Title:    Director

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	MERIDIAN SMALL CAP GROWTH FUND
	
	By: ArrowMark Colorado Holdings, LLC, its Investment Adviser
		
	By:	 	

	Name: Rick Grove
	Title: COO
	
	MERIDIAN GROWTH FUND
	
	By: ArrowMark Colorado Holdings, LLC, its Investment Adviser
		
	By:	 	

	Name: Rick Grove
	Title: COO
	
	ARROWMARK FUNDAMENTAL OPPORTUNITY FUND, L.P.
	
	By: ArrowMark Partners GP, LLC, its General Partner
		
	By:	 	 

  

	Name: Rick Grove
	Title: Authorized Signatory
	
	LOOKFAR INVESTMENTS, LLC
	
	By: ArrowMark Colorado Holdings, LLC, its Investment Adviser
		
	By:	 	

	Name: Rick Grove
	Title: COO

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	CF ASCENT LLC
	
	By: ArrowMark Colorado Holdings, LLC, its Investment Adviser
		
	By:	 	

	Name: Rick Grove
	Title: COO
	
	ARROWMARK LIFE SCIENCE FUND, LP
	
	By: ArrowMark Colorado Holdings, LLC, its Investment Adviser
		
	By:	 	

	Name: Rick Grove
	Title: COO
	
	IRON HORSE INVESTMENT, LLC
	
	By: ArrowMark Colorado Holdings, LLC, its Investment Adviser
		
	By:	 	

	Name: Rick Grove
	Title: COO

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	BAIN CAPITAL LIFE SCIENCES FUND II, L.P.
	
	By: Bain Capital Life Sciences Investors II, LLC, its general partner
	By: Bain Capital Life Sciences Investors, LLC, its manager
		
	By:	 	

	Name:	 	Andrew Hack
	Title:	 	Authorized Signatory
	
	BCIP LIFE SCIENCES ASSOCIATES, LP
	
	By: Boylston Coinvestors, LLC,
its general partner
		
	By:	 	

	Name:	 	Andrew Hack
	Title:	 	Authorized Signatory

 Signature Page to 2nd Amended and Restated
Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	FIDELITY MT. VERNON STREET TRUST:
	FIDELITY SERIES GROWTH COMPANY FUND
		
	By:	 	

	Name:	 	Chris Maher:
	Title:	 	Authorized Signatory
	
	FIDELITY MT. VERNON STREET TRUST:
	FIDELITY GROWTH COMPANY FUND
		
	By:	 	

	Name:	 	Chris Maher:
	Title:	 	Authorized Signatory
	
	FIDELITY GROWTH COMPANY COMMINGLED POOL
	
	By: Fidelity Management Trust Company, as Trustee
		
	By:	 	

	Name:	 	Chris Maher:
	Title:	 	Authorized Signatory
	
	FIDELITY MT. VERNON STREET TRUST:
	FIDELITY GROWTH COMPANY K6 FUND
		
	By:	 	

	Name:	 	Chris Maher:
	Title:	 	Authorized Signatory
	
	FIDELITY SELECT PORTFOLIOS:
	BIOTECHNOLOGY PORTFOLIO
		
	By:	 	

	Name:	 	Chris Maher:
	Title:	 	Authorized Signatory

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	FORESITE CAPITAL FUND V, L.P.
	
	By: Foresite Capital Management V, LLC
	Its: General Partner
		
	By:	 	

	Name:	 	Dennis D. Ryan
	Title:	 	Chief Financial Offer

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	GC&H INVESTMENTS, L.P.
	
	By: GC&H Management, LLC
		
	By:	 	

 
			
	Name:	 	Jim Kindler
	Title:	 	Authorized Signatory

 
			
	
	GC&H INVESTMENTS A1, L.P.
	
	By: GC&H Management, LLC
		
	By:	 	

 
			
	Name:	 	Jim Kindler
	Title:	 	Authorized Signatory

 Signature Page to 2nd Amended and Restated
Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	GV 2021, L.P.
	By: GV 2021 GP, L.P., its General Partner
	By: GV 2021 GP, L.L.C., its General Partner
		
	By:	 	

 
			
	Name:	 	Daphne M. Chang
	Title:	 	Authorized Signatory

 
			
	
	GV 2019, L.P.
	By:	 	GV 2019 GP, L.P., its General Partner
	By:	 	GV 2019 GP, L.L.C., its General Partner
		
	By:	 	

 
			
	Name:	 	Daphne M. Chang
	Title:	 	Authorized Signatory

 Signature Page to 2nd Amended and Restated
Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	HASHAM TRADERS

 
			
		
	By:	 	 

 
			
	 Name:
	 	 Manoj Jaiswal

	 Title: CFO and Operating Partner

 Signature Page to 2nd Amended and Restated
Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	MITHRIL II LP
	
	By: Mithril II GP LP, its General Partner
	By: Mithril II UGP LLC, its General Partner
		
	By:	 	

 
			
	Name:	 	Ajay Royan
	Title:	 	Managing Member

 Signature Page to 2nd Amended and Restated
Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	ORBIMED PRIVATE INVESTMENTS VII, LP
	
	By: OrbiMed Capital GP VII LLC,
its General Partner

 
			
	
	By: OrbiMed Advisors LLC,
its Managing Member
		
	By:	 	

 
			
	Name: Carl Gordon
	Title: Member

 Signature Page to 2nd Amended and Restated
Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	POLARIS PARTNERS IX, L.P.
	
	By: Polaris Partners GP IX, L.L.C.,
	Its: General Partner
		
	By:	 	

	Name: Lauren Crockett
	Title:   General Counsel
	
	POLARIS VENTURE PARTNERS FOUNDERS’ FUND V, L.P.
	
	By: Polaris Venture Management Co. V, L.L.C.,
	Its: General Partner
		
	By:	 	

	Name: Lauren Crockett
	Title:   Attorney-in-Fact
	
	POLARIS VENTURE PARTNERS V, L.P.
	
	By: Polaris Venture Management Co. V, L.L.C.,
	Its: General Partner
		
	By:	 	[

	Name: Lauren Crockett
	Title:   Attorney-in-Fact

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	POLARIS VENTURE PARTNERS
	ENTREPRENEURS’ FUND V, L.P.
	
	By: Polaris Venture Management Co. V, L.L.C.,
	Its: General Partner
		
	By:	 	

	Name: Lauren Crockett
	Title:   Attorney-in-Fact
	
	POLARIS VENTURE PARTNERS SPECIAL
	FOUNDERS’ FUND V, L.P.
	
	By: Polaris Venture Management Co. V, L.L.C.,
	Its: General Partner
		
	By:	 	

	Name: Lauren Crockett
	Title:   Attorney-in-Fact

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	POPULATION HEALTH EQUITY PARTNERS III, L.P.
	
	By: Population Health Equity Partners III GP, LLC, its General Partner
		
	By:	 	

	Name: Chris Cox
	Title:   Managing Member

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	POPULATION HEALTH EQUITY PARTNERS VII, L.P.
	
	By: Population Health Equity Partners VII GP, LLC, its General Partner
		
	By:	 	

	Name: Chris Cox
	Title:   Managing Member

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	REDMILE BIOPHARMA INVESTMENTS III, L.P.
	
	By: Redmile Biopharma Investments III (GP), LLC, its General Partner
		
	By:	 	

	Name: Joshua Garcia
	Title: Authorized Signatory
	
	RAF, L.P.
	
	By: RAF GP, LLC, its General Partner
		
	By:	 	

	Name: Joshua Garcia
	Title: Authorized Signatory

 Signature Page to 2nd Amended and Restated
Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	POLARIS HEALTHCARE TECHNOLOGY
	OPPORTUNITIES FUND, L.P.
	
	By: Polaris Healthcare Technology Opportunities Fund GP, L.L.C., its General Partner

 
			
		
	By:	 	

 
			
	Name: Lauren Crockett
	Title:   General Counsel

 Signature Page to 2nd Amended and Restated
Investors’ Rights Agreement 

 SCHEDULE A 

Investors 
 Name and Address

 Adimab, LLC 
 [***] 

Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund 

[***] 
 Fidelity Growth Company Commingled Pool 

[***] 
 Fidelity Mt. Vernon Street Trust: Fidelity Growth Company
K6 Fund 
 [***] 
 Fidelity Mt. Vernon Street Trust: Fidelity
Series Growth Company Fund 
 [***] 
 Fidelity Select
Portfolios: Biotechnology Portfolio 
 [***] 
 Jeffrey E.
Florman, M.D. 
 [***] 
 GV 2021, L.P. 

[***] 
 GV 2019, L.P. 

[***] 
 MRL Ventures Fund LLC 

[***] 
 Mithril II LP 

[***] 
 M28 Capital Master Fund LP 

[***] 
 Veltro Argento, LP 

[***] 

 OrbiMed Private Investments VII, LP 

[***] 
 Polaris Partners IX, L.P. 

[***] 
 Polaris Venture Partners V, L.P. 

[***] 
 Polaris Venture Partners Entrepreneurs’ Fund V, L.P.

 [***] 
 Polaris Venture Partners Founders’ Fund V, L.P.

 [***] 
 Polaris Venture Partners Special Founders’ Fund
V, L.P. 
 [***] 
 Polaris Healthcare Technology Opportunities
Fund, L.P. 
 [***] 
 VP Company Investments 2018, LLC 

[***] 
 Dikigoros Holdings LLC 

[***] 
 Paul G. Ambrose, Pharm.D. 

[***] 
 Matthew R. Conway 

[***] 
 Tim Downing 

[***] 
 Yaroslav Faybishenko 

[***] 
 Sabah Oney, Ph.D. 

[***] 
 Andrew Siegel 

[***] 

 Omega Fund VI, L.P. 

[***] 
 Population Health Equity Partners VII, L.P. 

[***] 
 Population Health Equity Partners III, L.P. 

[***] 
 RA Capital Healthcare Fund, L.P 

[***] 
 RA Capital NEXUS Fund II, L.P. 

[***] 
 GC&H Investments, L.P. 

[***] 
 GC&H Investments A1, L.P. 

[***] 
 Bain Capital Life Sciences Fund II, L.P. 

[***] 
 BCIP Life Sciences Associates, LP 

[***] 
 Redmile Biopharma Investments III, L.P. 

[***] 
 RAF, L.P. 

[***] 
 Hasham Traders 

[***] 
 Meridian Small Cap Growth Fund 

[***] 
 Meridian Growth Fund 

[***] 
 ArrowMark Fundamental Opportunity Fund, L.P. 

[***] 
 Lookfar Investments, LLC 

[***] 

 CF Ascent LLC 

[***] 
 ArrowMark Life Science Fund, LP 

[***] 
 Iron Horse Investment, LLC 

[***] 
 Foresite Capital Fund V, L.P. 

[***] 
 Federated Hermes Kaufmann Small Cap Fund 

[***] 
 Federated Hermes Kaufmann Fund 

[***] 
 Federated Hermes Kaufmann Fund II 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]